Cleveland Clinic-Led Study Finds Bevacizumab As Effective As FDA-Approved Ranibizumab In Treating Macular Degeneration
A new study published online today in The New England Journal of Medicine (NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab (Lucentis), the current Food and Drug Administration-approved drug for treating age-related macular degeneration (AMD).